

08:00	<b>Registration &amp; Coffee</b>						
08:15	<b>Welcome Speech by Beth Jacobs, Managing Partner, Excellentia Global Partners - Room Boston</b>						
08:30	<b>Public Markets and M&amp;A - Room Boston</b> Chaired by: Stephanie Léouzon, Principal and Head, Torrey Partners (Europe), LLC Panellists: Jim Phillips, CEO, Midatech Pharma PLC Jim Steel, Head of Healthcare and Life Sciences, Corporate Finance, Peel Hunt LLP Nicholas Franco, EVP & CBDO, Actelion Pharmaceuticals Ltd. Peter Homberg, Partner/Lawyer, Dentons Europe, LLC Rudi Pauwels, CEO, Biocartis NV Vivek Ramaswamy, CEO, Axovant Sciences	<b>For Wi-Fi please connect Sachs Forum Wi-Fi</b> <b>UserID: 2253442706</b> <b>Password: 4669</b>					
		<b>Personalised Medicine &amp; Diagnostics - Room Delhi</b> Co-Chaired: Alain Huriez, Partner, Advent Life Sciences Rainer Metzger, VP Global Business Development Pharma, QIAGEN GmbH Panellists: Anish Bhatnagar, President and CEO, Capnia, Inc. Bill Mullen, CEO, Momentum Bioscience Ltd. Eduardo Margallo, CEO, MedLumics S.L. João Pereira, CEO, Magnomics Miro Venturi, Global Head, Diagnostics Biomarkers, F.Hoffmann La Roche AG Stephen Zaniboni, CFO, Trovogene, Inc.	Presentation Track A - Room Darwin Moderated by: <b>Oliver Haslam</b>	Presentation Track B - Room Lima Moderated by: <b>Lorenza Castellon</b>			
09:15	<b>Investors &amp; Analysts - Room Boston</b> Chaired by: Bob Pooler, Sr. Healthcare Analyst, valuationLAB AG Panellists: Chris Marai, Executive Director, Oppenheimer & Co. Christian Lach, Portfolio Manager, Analyst, Bellevue Asset Management AG Daniel Anizon, Financial Analyst, Independent Consultant Ivo Staijen, CFA, HBM Partners AG Stephen Brozak, Managing Partner and President, WBB Securities, LLC	08:45					
10:00	<b>Raising Capital Outside Europe - Boston</b> Chaired by: Beth Jacobs, Managing Partner, Excellentia Global Partners Panellists: Adam Kostyál, Senior Vice President, Nasdaq OMX Chris Maggos, Managing Director, Europe, LifeSci Advisors David Stueber, Managing Director, BNY Mellon Saad Gilani, Managing Director & Head of Healthcare Investments, Yorkville Advisors, LLC Thomas Stockman, Director, Healthcare Investment Banking, RBC	09:45	<b>Vaccines - Room Delhi</b> Co-Chaired: Chris Britten, Managing Director, Torrey Partners (Europe), LLC Florian Schödel, Owner, Philimmune, LLC Panellists: Jeff Baxter, CEO, VBI Vaccines Joel Crouzet, CEO & CSO, InnaVirVax Katherine Cohen, CEO, Hookipa Biotech AG Oliver Siegel, CEO, AFFiRiS AG Ronald Kempers, President and CEO, Mymetics Corporation	09:00	Re-Pharm Ltd.	09:00	Minoryx Therapeutics S.L.
			09:15	Rebiotix, Inc.	09:10	Genkyotex S.A.	
			09:30	Pharmaco-Kinesis Corporation	09:20	Rexahn Pharmaceuticals, Inc.	
			09:45	CEVEC Pharmaceuticals GmbH	09:30	Randox Biosciences Companion Diagnostics Development	
			10:00	Selexis SA	09:40	PNBDevCo	
			10:15	Pantec Biosolutions AG	09:50	Gabather AB	
		10:30	Hansa Medical AB	10:00	Autifony Therapeutics Ltd.		
				10:10	Athera Biotechnologies AB		
				10:20	Abionic SA		
				10:30	Magnomics		
10:45	<b>Coffee Break</b>						

2015 Host Sponsor:



Reception Sponsor:



Kanton Basel-Stadt

Silver Sponsors:



TORREYA PARTNERS

11:00	<b>Interview</b> by Fintan Walton, CEO, PharmaVentures Ltd. - <b>Room Boston</b> <b>Jason Coloma</b> , Head of Oncology and Cancer Immunology, Roche Partnering, F. Hoffmann La Roche AG	11:00	<b>Orphan &amp; Rare Diseases - Room Delhi</b> Chaired by: Detlev Mennerich, Investment Manager, Boehringer Ingelheim Venture Fund GmbH Panellists: Charlie Alexander, Lead-BD Transactions, Shire Pharmaceutical Jutta Roth, Business Development Manager, University of Oxford Marc Martinell, Chief Executive Officer, Minoryx Therapeutics S.L. Mark Pykett, CEO, Agilis Biotherapeutics, LLC Nanna Lüneborg, Investment Director, Novo A/S Stephen Helliwell, Senior Investigator, Novartis Institutes for BioMedical Research	Presentation Track C - Room Darwin Moderated by: <b>Robin Davison</b>		Presentation Track D - Room Lima Moderated by: <b>Tomas Kahn</b>	
11:20	<b>Late Stage Investment - Room Boston</b> Chaired by: Genghis Lloyd-Harris, Partner, Abingworth LLP Panellists: Arthur Franken, Partner, Gilde Healthcare Partners Carole Nuechterlein, Head, Roche Venture Fund Deborah Harland, Partner, S.R. One Ltd. Joshua Resnick, President, MRL Ventures Markus Goebel, Partner, Novartis Venture Fund Markus Hosang, General Partner, BioMedPartners AG Naveed Siddiqi, Partner, Edmond de Rothschild Investment Partners			11:00	Anagenesis Biotechnologies	11:00	Addex Therapeutics Ltd.
11:20		12:00	<b>Platform Technologies &amp; Novel Therapeutics - Room Delhi</b> Co-Chaired by: David Colpman, Director, Colpman Consulting Ltd. David Phillips, Partner, S.R. One Ltd. Panellists: Chris Moriarty, Global Manager, Pharma Sciences Division, Randox Biosciences Elias Papatheodorou, CBO, Genkyotex S.A. Geert Cauwenbergh, President and CEO, RXi Pharmaceuticals Corporation Maarit Merla, Head of Business Development, Forendo Pharma Ltd. Melya Hughes Cramer, Head of BD, Europe, Amunix Operating Inc. Philippe Calais, CEO, Isarna Therapeutics GmbH Vikas Sharma, Director, BD, Rexahn Pharmaceuticals, Inc.	11:10	eTheRNA	11:15	Isarna Therapeutics GmbH
11:20				Acousia Therapeutics GmbH			
11:30				Therabron Therapeutics	11:30	Flexion Therapeutics	
11:40				Mymetics Corporation	11:45	Achelos Therapeutics, Inc.	
11:50				InnaVirVax			
12:00	AFFiRiS AG	12:00	KineMed, Inc.				
12:15	Tonix Pharmaceuticals Holding Corp.	12:15	Heptares Therapeutics				
12:30	Hookipa Biotech AG	12:30	Probiodrug AG				
12:45	VBI Vaccines	12:45	Axovant Sciences				
13:00	<b>Networking Lunch</b>						

Supporters:



14:00	<b>Cell and Gene Therapies: Recent Advances - Room Boston</b> Co-Chaired by: Christian Glennie, Head of Research, Healthcare, Edison Investment Research Rao Movva, Novartis Distinguished Scientist / Scout-Collaborations, Novartis Institutes for BioMedical Research Panellists: Martin McGlynn, President & CEO, StemCells, Inc. Matthew Durdy, CBO, Cell Therapy Catapult Pedro Lichtinger, CEO, Asterias Biotherapeutics Peter Nolan, CBO, Oxford Biomedica Ltd. Stéphane Boissel, CEO, TxCell SA Wim Jongen, CEO, Glycostem Therapeutics	14:00	<b>Infectious Diseases - Room Delhi</b> Chaired by: Laurenz Kellenberger, CSO, Basilea Pharmaceutica Intern. Panellists: B. Chandler May, President and CEO, Inflammatory Response Research, Inc. Marc Gitzinger, CEO and Co-Founder, BioVersys AG Matt Adams, VP Tech Ops and Business Development, Rebiotix, Inc. Nicholas Benedict, CEO & Co-Founder, Allecra Therapeutics	Presentation Track E - Room Darwin Moderated by: <b>Daniel Gooch</b>		Presentation Track F - Room Lima Moderated by: <b>Wilder Fulford</b>			
			14:00	Abzena PLC	14:00	Capnia, Inc.			
			14:15	AcelRx Pharmaceuticals, Inc.	14:15	Midatech Pharma PLC			
			14:30	Aptose Biosciences, Inc.	14:30	Trovagene, Inc.			
			14:45	MISSION Therapeutics Ltd.	14:45	Agilis Biotherapeutics, LLC			
			15:00	Immune Pharmaceuticals, Inc.	15:00	Numab AG			
			15:15	Galena Biopharma, Inc.	15:15	RXi Pharmaceuticals, Corp.			
			15:30	<b>Coffee Break</b>					
15:45	<b>Interview</b> by Fintan Walton, CEO, PharmaVentures Ltd. - Room Boston <b>Susan Herbert</b> , EVP, Head of Global BD & Alliance Management, Merck KGaA	15:45	<b>"Rescuing Drugs: A New Strategy For Addressing Unmet Medical Need"</b> <b>Vivek Ramaswamy</b> , CEO, Axovant Sciences	Presentation Track G - Room Darwin Moderated by: <b>Joergen Thorball</b>		Presentation Track H - Room Lima Moderated by: <b>Beth Jacobs</b>			
16:15	-	16:05	<b>Neuroscience &amp; Pain I - CNS - Room Delhi</b> Chaired by: Klaus Mendla, Global Head, BD & Licensing CNS, Boehringer Ingelheim Pharma GmbH & Co. KG Panellists: Erik Buntinx, Founding CEO, PNBDevCo Hendrik Liebers, CFO, Probiobdrug AG Malcolm Weir, Co-Founder and CEO, Heptares Therapeutics Patrick Doyle, President, KineMed, Inc. Tim Dyer, CEO, Addex Therapeutics Ltd.	15:45	InDex Pharmaceuticals AB	15:45	Asterias Biotherapeutics		
16:30	<b>WuXi AppTech, Inc.</b>			15:55	BioVersys AG	16:00	Glycostem Therapeutics		
16:45	<b>Theradex (Europe) Ltd.</b>			16:05	Allecra Therapeutics	16:15	Inflammatory Response Research, Inc.	16:15	Oxford BioMedica PLC
SPACE FOR NOTES:				16:25	ObsEva SA	16:30	StemCells, Inc.		
				16:35	TocopheRX, Inc.				

17:00	<b>Academic Collaborations &amp; Tech Transfer - Room Boston</b> Co-Chaired by: Edwin Constable, Head of Research, Professor of Chemistry at the University of Basel and Project leader and Member of the Management Board within the SNI Luc Otten, Business Development, Alpine Institute for Drug Discovery Panellists: Jana Watson-Capps, Associate Director, University of Colorado BioFrontiers Institute Lars Gredsted, Senior Business Analyst, Wellcome Trust Laura Lane, Business Development Manager, Warwick Ventures Ltd. Maria Hassard, Deputy Director of Research & Development, Moorfields Biomedical Research Centre Nicola Thompson, Head, Office of External Drug Discovery, F. Hoffmann La Roche AG Pascale Auge, CEO, Inserm Transfert	16:40	<b>Neuroscience &amp; Pain II - PAIN - Room Delhi</b> Chaired by: Fabrizio Gasparini, Director, Novartis Institutes for BioMedical Research Panellists: Crist Frangakis, CEO and President, Achelios Therapeutics, Inc. Leland Gershell, CFO, Tonix Pharmaceuticals Holding Corp. Masa Yuhara, General Manager, BD, Mitsubishi Tanabe Pharma Europe Ltd. Rahul Ballal, Director, BD, Flexion Therapeutics Timothy Morris, CFO, Head of BD, AcetRx Pharmaceuticals, Inc.	Continued Presentation Track G - Room Darwin Moderated by: <b>Joergen Thorball</b>		Continued Presentation Track H - Room Lima Moderated by: <b>Beth Jacobs</b>	
			16:45	Saphetor	16:45	TxCell SA	
			16:55	MedLumics S.L.	17:00	CymaBay Therapeutics	
			17:05	Aptahem AB			
			17:15	TBC	17:15	Michelson Diagnostics Ltd.	
			17:25	Forendo Pharma Ltd.			
			17:35	TBC	17:30	Biophytis	
			17:45	TBC			
17:15	<b>Autoimmune &amp; Inflammatory - Room Delhi</b> Co-Chaired by: Jane Atkins, Director, Search & Evaluation, Centre for External Innovation, Takeda Pharmaceuticals International GmbH Lubor Gaal, Head of Licensing and External Innovation, Almirall S.A. Panellists: Celia Zinger, Director Medical Affairs, Immune Pharmaceuticals, Inc. Kia Motesharei, Head of Global Licensing & BD, Immunology, EMD Serono Nathalie ter Wengel, Director of Business Development, Galapagos Peter Zerhouni, CEO, InDex Pharmaceuticals AB Simon Blake, Sr. Director, Scientific Licensing for Immunology, J&J Thomas Hanke, EVP Immunology & Inflammation, Evotec International GmbH						
18:00	<b>End of Day One</b>						
19:00	<b>Networking Reception at the Grand Hotel "Les Trois Rois" sponsored by Kanton Basel-Stadt</b>						
21:00	<b>End of Reception</b>						

2015 Host Sponsor:



Reception Sponsor:



Silver Sponsors:



08:00 Registration & Coffee					
09:00	<b>Partnering I – Early Stage - Room Boston</b> Co-Chaired by: Chris Britten, Managing Director, Torrey Partners (Europe) LLP Fintan Walton, CEO, PharmaVentures Ltd. Panellists: Iain Dukes, SVP Business Development & Licensing, Merck Research Laboratories Loic Vincent, Head, Oncology External Innovation, Sanofi Maria Flocco, Senior Director, Head Strategic Research, Pfizer Anand Gautam, Director, R&D Innovation Sourcing, Novo Nordisk A/S Tim Luker, Senior Director, External Innovation, Corporate Business Development, Eli Lilly & Company Shane Maloney, Business Development Director, AstraZeneca	Presentation Track A - Room Darwin Moderated by: <b>Tomas Kahn</b>		Presentation Track B - Room Lima Moderated by: <b>Joergen Thorball</b>	
		09:00	Nanobiotix	09:00	TBA
		09:15	Oryx GmbH & Co. KG	09:10	Amunix Operating, Inc.
		09:30	Metys Pharmaceuticals AG	09:20	MiNA Therapeutics
		09:45	ImmunID	09:30	TREEWAY BV
		10:00	Prophylix Pharma, Inc.	09:40	Cell Therapy Ltd.
		10:15	Oryzon Genomics	09:50	4D Lifetec AG
		10:30	TBA	10:00	Genclis SAS
10:00	<b>Partnering II – Late Stage - Room Boston</b> Co-Chaired by: Chris Britten, Managing Director, Torrey Partners (Europe) LLP Fintan Walton, CEO, PharmaVentures Ltd. Panellists: Donnie Mcgrath, Vice President Business Development, Bristol-Myers Squibb Frederic Desdouits, Head of Corporate BD & Acquisitions, Pierre Fabre Philippe Lopes-Fernandes, Senior Vice-President, Head of Global Licensing & Business Development, MERCK Serono / EMD Serono, Inc.	10:10	ViraTherapeutics GmbH	10:20	Microbial Robotics
		10:30	Takis S.r.l.		

10:45 Coffee Break

2015 Host Sponsor:



Reception Sponsor:



Silver Sponsors:



TORREYA PARTNERS

		Presentation Track C - Room Darwin Moderated by: <b>Hans Herklots</b>	Presentation Track D - Room Lima Moderated by: <b>Lorenza Castellon</b>
11:00	<b>Oncology I – Early Stage - Room Boston</b> Chaired by: Tim Herpin, Head of Transactions team, AstraZeneca AB Panellists: Austin Smith, Medical Director, Theradex (Europe) Ltd. Bernhard Sixt, CEO, ImmunID Bernard Bihain, CEO, Genclis SAS Bernard Huber, Chief Executive Officer and Founder, Oryx GmbH & Co. KG Prof. Dorothee Holm-von Laer, Co-founder and CEO, ViraTherapeutics GmbH Michael Scherz, Founder & CEO, Metys Pharmaceuticals AG	11:00 Cristal Therapeutics	11:00 TheraSolve NV
		11:15 Nordic Nanovector ASA	11:10 Plant Advance Technologies PAT
		11:30 OncoSec Medical, Inc.	11:20 Eyevensys
		11:45 Provectus Biopharmaceuticals, Inc.	11:30 Atriva Therapeutics GmbH
		12:00 TBA	11:40 Haemostatix Ltd.
		12:15 SurgiMab SAS	11:50 Available
		12:30 ArmaGen, Inc.	12:00 Available
		12:45 TBA	12:10 Available
			12:20 Available
			12:30 Available
			12:40 Available
			12:50 Available
13:00	<b>Networking Lunch</b>		
14:00	<b>Oncology III – Pharma/Biotech BD&amp;L - Room Boston</b> Co-Chaired by: François Thomas, Managing Director, Thomas Conseil SPRL Peter Hoang, Senior Vice President, Business Development & Strategy, Bellicum Pharmaceuticals, Inc. Panellists: David Meininger, Senior Vice President Business Development, OncoSec Medical, Inc. Georg Buchner, Licencing Director Europe, Amgen, Inc. Loic Vincent, Head, Oncology External Innovation, Sanofi	<b>For Wi-Fi please connect Sachs Forum Wi-Fi</b> <b>UserID: 2253442706</b> <b>Password: 4669</b>	
15:00	<b>Interactive Workshop by Nigel Borshell, Vice President, PharmaVentures Ltd. - Room Boston</b> <b>“Founder’s equity – Dilute to taste! ... Exploring participants’ intuitive feelings for value around early stage company equity splits in a developing case history based scenario.”</b>		
16:30	<b>Last Chance to Network</b>		
17:00	<b>End of the Forum</b>		